Current Market Access to Avsola, Inflectra and Remicade

While biosimilars Avsola and Inflectra are picking up ground, Remicade is still more advantaged, holding covered or better status for 61% of all insured lives.

NOTE: Access that requires prior authorization and/or step therapy is represented by the abbreviation (PA/ST). 274.0 million lives are covered under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 7/12/21.

0

0

0 Comments

0

0

• Spotlight on Market Access